Mebeverine is a musculotropic antispasmodic with a direct action on the smooth muscle of the gastrointestinal tract, without affecting normal gut motility.


Each hard gelatin capsule contains:
Mebeverine hydrochloride BP 200 mg
(In Sustained Release form)

Indications for use

  • Symptomatic treatment of abdominal pain and cramps, bowel disturbances and intestinal discomfort related to irritable bowel syndrome.
  • Treatment of gastro-intestinal spasm secondary to organ diseases.

Mode of administration

Adults (including the elderly):
One capsule of 200 mg twice daily, to be given one in the morning and one in the evening.
Paediatric Population:
Delispaz 200 mg sustained release capsules are not recommended for use in children and adolescents below 18, due to insufficient data on safety and efficacy.
Duration of use is not limited.
If one or more doses are missed, the patient should continue with the next dose as prescribed; the missed dose(s) should not be taken in addition to the regular dose.
Special Population:
No posology studies in elderly, renal and/or hepatic impaired patients have been performed. No specific risk for elderly, renal and/or hepatic impaired patients could be identified from available post-marketing data. No dosage adjustment is deemed necessary in elderly, renal and/or hepatic impaired patients.